Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $187 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $187 price target.
June 07, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reiterated an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $187 price target.
The reiteration of the Outperform rating and maintenance of the $187 price target by Wedbush analyst Andreas Argyrides indicates a positive outlook for Ascendis Pharma. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100